April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Safety and Efficacy of Ranibizumab Treatment in Patients With Diabetic Macular Edema: 12-Months Results of the Resolve Study
Author Affiliations & Notes
  • S. Wolf
    Universitatsklinik fur Augenheilkunde,
    University of Bern, Bern, Switzerland
  • P. Massin
    Hôpital Lariboisière, Paris, France
  • F. Bandello
    Depart. Ophthalmology, University of Udine, Udine, Italy
  • D. Sharp
    Retina Specialists, Parnell, New Zealand
  • P. Lanzetta
    Depart. Ophthalmology, University of Udine, Udine, Italy
  • M. Larsen
    Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
  • U. Wolf-Schnurrbusch
    Bern Photographic Reading Center,
    University of Bern, Bern, Switzerland
  • M. Gekkieva
    Novartis Pharma AG, Basel, Switzerland
  • RESOLVE Study Group
    University of Bern, Bern, Switzerland
  • Footnotes
    Commercial Relationships  S. Wolf, Novartis, Pfizer, F; Novartis, Allergan, Pfizer, Takeda, C; Novartis, Allergan, Takeda, R; P. Massin, Novartis, R; Novartis, F; Novartis, Takeda, Solvay, Allergan, Elli Lilly, C; F. Bandello, Novartis, Allergan, F; Novartis, Pfizer, Baush & Lomb, Solvay, Allergan, Alcon, C; D. Sharp, None; P. Lanzetta, Novartis, F; Novartis, Neovista, C; Iridex, P; Novartis, Allergan, QLT, R; M. Larsen, Novartis, F; Novartis, R; U. Wolf-Schnurrbusch, Novartis, F; Novartis, Bausch&Lomb, R; M. Gekkieva, Novartis Pharma AG, E.
  • Footnotes
    Support  This study was sponsored by Novartis Pharma
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4331. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Wolf, P. Massin, F. Bandello, D. Sharp, P. Lanzetta, M. Larsen, U. Wolf-Schnurrbusch, M. Gekkieva, RESOLVE Study Group; Safety and Efficacy of Ranibizumab Treatment in Patients With Diabetic Macular Edema: 12-Months Results of the Resolve Study. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4331.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Evaluate safety and explore effect of ranibizumab in diabetic macular edema (DME).

Methods: : Multi-center, double-masked study involving 151 DME patients treated over 12 months with 6 mg/ml ranibizumab (n=51), 10 mg/ml ranibizumab (n=51), or sham injection (n=49). Three initial monthly injections followed by re-treatment based on success, futility, or safety criteria. Injection volume doubled as of Month 1 if central retinal thickness (CRT) was >300 µm or >225 µm and reduction from prior assessment <50 µm. Laser photocoagulation as rescue medication allowed from Month 3 onwards. Best-corrected visual acuity (BCVA; Early Treatment for Diabetic Retinopathy Study charts) and CRT (optical coherence tomography) were assessed monthly.

Results: : Injection volume doubled in 92% sham and 73/65% ranibizumab patients (6/10 mg/ml). Rescue treatment in 33% sham and 9% ranibizumab patients. Over 12-months, most frequent ocular adverse events (AEs): conjunctival hemorrhage (14% sham, 23% ranibizumab); eye pain (20% sham, 18% ranibizumab). Serious ocular AEs: 1 sham patient (retinal detachment), 4 ranibizumab patients (endophthalmitis, transient retinal artery occlusion, peripheral retinal ischemia). Non-ocular arterial thromboembolic events: 2 sham and 3 ranibizumab (10 mg/ml) patients. Mean BCVA increased and mean CRT decreased continuously over time in ranibizumab patients. Mean change in BCVA from baseline to Month 12 was -1.4 letters (sham) +11.8 letters (6 mg/ml), +8.8 letters (10 mg/ml), and +10.3 letters (pooled ranibizumab groups).

Conclusions: : Safety of ranibizumab in DME was comparable to previous studies of neovascular AMD. Ranibizumab treatment demonstrated superior efficacy to sham treatment in DME and was associated with continuous improvement in BCVA and CRT throughout 12 months.

Clinical Trial: : www.clinicaltrials.gov NCT00284050

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • diabetic retinopathy • visual acuity 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.